[
    {
        "startTime": 466,
        "endTime": 3706,
        "text": "There could be a new treatment in the fight against COVID."
    },
    {
        "startTime": 4103,
        "endTime": 6559,
        "text": "Regeneron said it's pursuing US approval..."
    },
    {
        "startTime": 6695,
        "endTime": 10907,
        "text": "...for its COVID-19 antibody cocktail as a preventative treatment..."
    },
    {
        "startTime": 11264,
        "endTime": 14944,
        "text": "...after it helped cut the risk of symptomatic infections in households..."
    },
    {
        "startTime": 15181,
        "endTime": 16803,
        "text": "...where someone else is ill."
    },
    {
        "startTime": 16980,
        "endTime": 19579,
        "text": "According to trial data released by the company,..."
    },
    {
        "startTime": 19879,
        "endTime": 23256,
        "text": "...the drug protected household contacts exposed to COVID..."
    },
    {
        "startTime": 23551,
        "endTime": 26630,
        "text": "...from ever developing symptoms in the majority of the cases..."
    },
    {
        "startTime": 26985,
        "endTime": 31727,
        "text": "...with 72 percent protection against symptomatic infections in the first week..."
    },
    {
        "startTime": 32088,
        "endTime": 34412,
        "text": "...and 93 percent after that."
    },
    {
        "startTime": 34631,
        "endTime": 37305,
        "text": "Regeneron has enlisted Switzerland's Roche..."
    },
    {
        "startTime": 37378,
        "endTime": 41169,
        "text": "...and its massive biotech facility in south San Francisco..."
    },
    {
        "startTime": 41293,
        "endTime": 43968,
        "text": "...to make around two million doses annually."
    },
    {
        "startTime": 44224,
        "endTime": 47213,
        "text": "The cocktail already has emergency US approval..."
    },
    {
        "startTime": 47315,
        "endTime": 49680,
        "text": "...for patients with mild to moderate COVID..."
    },
    {
        "startTime": 50056,
        "endTime": 52183,
        "text": "...and the companies are hoping the latest trials..."
    },
    {
        "startTime": 52325,
        "endTime": 55397,
        "text": "...convince regulators to expand deployment."
    },
    {
        "startTime": 55541,
        "endTime": 57902,
        "text": "Medical experts say it could be useful..."
    },
    {
        "startTime": 57989,
        "endTime": 60236,
        "text": "...to control outbreaks in high-risk settings..."
    },
    {
        "startTime": 60563,
        "endTime": 63006,
        "text": "...where people haven't been vaccinated."
    }
]